Gain Therapeutics, Inc. (GANX)

In November 2025, Gain Therapeutics reported positive Q3 results and clinical updates for GT-02287, leading to a stock increase. In December 2025, the company announced positive results from its Phase 1b clinical study of GT-02287, and analysts increased price targets. On January 6, 2026, the company highlighted biomarker evidence supporting GT-02287's potential. On January 7, 2026, the stock closed down despite participation in the J.P. Morgan Healthcare Conference. On January 9, 2026, shares closed down following the announcement of early Phase 1b data for GT-02287. As of September 30, 2025, the company reported insufficient cash to fund operations for a full year, raising doubts about its ability to continue without new capital.

Demand seasonality is not directly applicable to Gain Therapeutics, Inc. as it is a clinical-stage biotechnology company without commercialized products or services generating sales revenue. The company's financial activities are centered on funding its clinical trials and advancing its pipeline.

Gain Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing novel small molecule therapeutics, operating within the Healthcare sector, specifically in the Biotechnology industry. The company utilizes its proprietary computational target and drug discovery platform, Magellan™, which employs AI-supported 3D structural biology and supercomputer-powered physics-based models to identify novel allosteric binding sites on misfolded proteins and discover small molecules that modulate protein function. Its primary product focus is GT-02287, currently in Phase 1b clinical trials for Parkinson's disease, and it has a pipeline of other drug candidates targeting conditions like Gaucher disease, Alzheimer's disease, and solid tumors.

Gain Therapeutics operates in Switzerland, Spain, the United States, and Australia and is headquartered in Bethesda, Maryland, United States.

Gain Therapeutics' brand reputation is shaped by its scientific advancements and market perception. The company has a "Moderate Buy" consensus rating from analysts, and its Magellan™ platform is recognized for its innovative approach to drug discovery. Positive clinical updates for GT-02287 have contributed positively to its scientific standing. Concerns about the company's cash runway and potential share dilution could temper its overall brand perception among investors.

Gain Therapeutics, Inc. has 47 institutional owners and shareholders, holding a total of 4,461,322 shares. Individual insiders hold approximately 3.48% of the shares, while the general public holds about 85%.